Outcomes of patients with blastoid and pleomorphic variant mantle cell lymphoma
Year: 2023
Type: article
Study design: Observational Study
Abstract: Mantle cell lymphoma (MCL) is a B-cell non-Hodgkin lymphoma; data indicate that blastoid and pleomorphic variants have a poor prognosis. We report characteristics and outcomes of patients with blastoid/pleomorphic variants of MCL. We retrospectively studied adults with newly diagnosed MCL treated from 2000 to 2015. Primary objectives were to describe progression-free survival (PFS) and overall survival (OS). Secondary objectives included characterization of patient characteristics and treatments. Of the 1029 patients with MCL studied, a total of 207 neoplasms were blastoid or pleomorphic variants. Median follow-up period was 82 months (range, 0.1-174 months); median PFS was 38 months (95% confidence interval [CI], 28-66) and OS was 68 months (95% CI, 45-96). Factors associated with PFS were receipt of consolidative autologous hematopoietic transplantation (auto-HCT; hazard ratio [HR], 0.52; 95% CI, 0.31-0.80; P < .05), MCL International Prognostic Index (MIPI) intermediate (HR, 2.3; 95% CI, 1.2-4.3; P < .02) and high (HR, 3.8; 95% CI, 2.0-7.4; P < .01) scores, and complete response to induction (HR, 0.29 (95% CI, 0.17-0.51). Receipt of auto-HCT was not associated with OS (HR, 0.69; 95% CI, 0.41-1.16; P = .16) but was associated with MIPI intermediate (HR, 5.7; 95% CI, 2.5-13.2; P < .01) and high (HR, 10.8; 95% CI, 4.7-24.9; P < .01) scores. We report outcomes in a large cohort of patients with blastoid/pleomorphic variant MCL. For eligible patients, receipt of auto-HCT after induction was associated with improved PFS but not OS. Higher MIPI score and auto-HCT ineligibility were associated with worse survival.
Source: Blood Advances
Authors: James N. Gerson, Elizabeth Handorf, Diego Villa, Alina S. Gerrie, Parv Chapani, Shaoying Li, L. Jeffrey Medeiros, Michael Wang, Jonathon B. Cohen, Michael Churnetski, Brian T. Hill, Yazeed Sawalha, Francisco J. Hernandez-Ilizaliturri, Shalin Kothari, Julie M. Vose, Martin Bast, Timothy Fenske, Swapna Narayana Rao Gari, Kami J. Maddocks, David Bond, Veronika Bachanova, Bhaskar Kolla, Julio Chavez, Bijal Shah, Frederick Lansigan, Timothy Burns, Alexandra M. Donovan, Nina Wagner-Johnston, Marcus Messmer, Amitkumar Mehta, Jennifer K. Anderson, Nishitha Reddy, Alexandra E. Kovach, Daniel J. Landsburg, Martha Glenn, David J. Inwards, Kay Ristow, Reem Karmali, Jason B. Kaplan, Paolo F. Caimi, Saurabh Rajguru, Andrew Evens, Andreas Klein, Elvira Umyarova, Bhargavi Pulluri, Jennifer E. Amengual, Jennifer K. Lue, Catherine Diefenbach, Richard I. Fisher, Stefan K. Barta
Institutions: Fox Chase Cancer Center, University of Pennsylvania, The University of Texas MD Anderson Cancer Center, Emory University, Cleveland Clinic, Roswell Park Comprehensive Cancer Center, Medical College of Wisconsin, The Ohio State University, University of Minnesota, Moffitt Cancer Center, Dartmouth–Hitchcock Medical Center, Johns Hopkins University, University of Alabama at Birmingham, Vanderbilt-Ingram Cancer Center, Huntsman Cancer Institute, Mayo Clinic, Northwestern University, Case Western Reserve University, University of Wisconsin–Madison, Tufts University, University of Vermont, Columbia University, New York University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
Estimated APC paid: $3,000
Funders: Amgen, Bristol-Myers Squibb, Pfizer, AstraZeneca, Sanofi, Gilead Sciences, Teva Pharmaceutical Industries, Spectrum Pharmaceuticals, Celgene, Karyopharm Therapeutics, Jazz Pharmaceuticals, Astex Pharmaceuticals, LAM Therapeutics, MEI Pharma, Adaptive Biotechnologies, Unum Therapeutics, Janssen Scientific Affairs, Incyte, Bayer HealthCare, National Institutes of Health, Genentech, Takeda Oncology, Kite Pharma, Pharmacyclics, Juno Therapeutics, Legend Biotech, National Cancer Institute, Janssen Biotech, National Center for Advancing Translational Sciences
OpenAlex ID: W4387900882
